Cardlytics, Inc. (NASDAQ:CDLX) Given Consensus Recommendation of “Hold” by Brokerages

Cardlytics, Inc. (NASDAQ:CDLX) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $6.92.

A number of analysts recently weighed in on the stock. Evercore ISI began coverage on shares of Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price objective for the company. Northland Securities downgraded shares of Cardlytics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $7.00 to $5.00 in a research note on Friday, August 16th. Northland Capmk cut Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Bank of America lowered Cardlytics from a “neutral” rating to an “underperform” rating and reduced their price target for the stock from $4.00 to $3.50 in a research report on Thursday, August 15th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th.

Cardlytics Price Performance

CDLX opened at $3.38 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The business has a fifty day moving average of $3.72 and a 200 day moving average of $6.41. Cardlytics has a 52-week low of $2.89 and a 52-week high of $20.52. The stock has a market cap of $171.77 million, a P/E ratio of -0.55 and a beta of 1.61.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.18. The company had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The firm’s revenue was down 15.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.26) EPS. As a group, sell-side analysts anticipate that Cardlytics will post -1.72 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares of the company’s stock, valued at $687,298.15. The trade was a 11.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Alexis Desieno sold 25,118 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the sale, the chief financial officer now directly owns 116,481 shares in the company, valued at approximately $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 68,691 shares of company stock valued at $237,767. 4.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cardlytics

A number of hedge funds and other institutional investors have recently made changes to their positions in CDLX. Price T Rowe Associates Inc. MD boosted its holdings in Cardlytics by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after buying an additional 1,774 shares in the last quarter. Canton Hathaway LLC boosted its stake in shares of Cardlytics by 95.7% during the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock worth $37,000 after acquiring an additional 2,200 shares in the last quarter. Check Capital Management Inc. CA grew its position in shares of Cardlytics by 10.4% during the 3rd quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company’s stock valued at $162,000 after acquiring an additional 4,775 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Cardlytics by 32.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock valued at $63,000 after purchasing an additional 4,796 shares in the last quarter. Finally, Creative Planning raised its holdings in Cardlytics by 35.4% in the 3rd quarter. Creative Planning now owns 29,537 shares of the company’s stock worth $95,000 after purchasing an additional 7,721 shares during the period. Institutional investors and hedge funds own 68.10% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.